The Scottish Food and Drug Administration (FDA) has recently approved a new drug for cancer patients and cure a child based on genetic movements rather than the type of disease.
The drug called Vitrakvi and the LAROTECTINIB scientific name has been approved for the use of canals that come to any place in the body.
NITCAVI is the first drug designed to combat the genetic behavioral of illness, irrespective of the type of cancer. , NBC said.
FDA agreement is an important step in cancer treatment, "FDA Commissioner Scott Gottlieb said in a statement." Origin of a tumor gene, wherever they are coming out in the cell; body. "
"This will help patients get" time-consuming, "he said.
He said that the drug is dealing with people with different tanners but they have common genetic movements, saying that this was not available for ten years ago due to & # 39; Knowledge of genetic modes is less than it is now.